Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/08880010802016375 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cerebrospinal Fluid Cytokine and Chemokine Analysis in Dogs With Meningoencephalitis of Unknown Origin or Idiopathic Epilepsy.
J Vet Intern Med
August 2025
College of Veterinary Medicine, Cornell University Hospital for Animals, Ithaca, New York, USA.
Background: Current diagnosis of brain disease in dogs is dependent on imaging and cerebrospinal fluid (CSF) analysis, including total nucleated cell counts and albumin concentrations.
Hypothesis/objectives: To determine whether multiplex cytokine/chemokine (Ct/Cm) analysis can differentiate among dogs with meningoencephalitis of unknown origin (MUE), idiopathic epilepsy (IE), and brain neoplasia.
Animals: Client owned dogs diagnosed with brain disease with MRI and CSF diagnostics.
Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial.
EClinicalMedicine
July 2025
Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain.
Background: Neutropenia and diarrhea are common sacituzumab govitecan-related adverse events, frequently leading to treatment modifications. PRIMED evaluated primary prophylactic granulocyte colony-stimulating factor (G-CSF) and loperamide to improve sacituzumab govitecan tolerability.
Methods: PRIMED (NCT05520723) was an open-label, single-arm, phase II study that enrolled HER2-negative advanced breast cancer patients previously treated with 1-2 chemotherapy regimens for metastatic disease.
Introduction: Benralizumab is an interleukin 5-receptor-blocking drug registered for the treatment of eosinophilic asthma. It has proven efficient and safe in a small phase-II trial in hypereosinophilic syndrome and is currently being investigated in a larger, randomized phase-III trial. We report on real-world experience with benralizumab in 15 patients with severe Hypereosinophilic syndrome (HES) that were refractory to other treatments or on unacceptable steroid doses.
View Article and Find Full Text PDFRepurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin Disorders.
Biomolecules
November 2024
Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, Italy.
Neutrophil-mediated inflammation is a key feature of immune-mediated chronic skin disorders, but the mechanistic understanding of neutrophil involvement in these conditions remains incomplete. Dapsone, colchicine, and tetracyclines are established drugs within the dermatologist's therapeutic armamentarium that are credited with potent anti-neutrophilic effects. Anti-neutrophilic drugs have established themselves as versatile agents in the treatment of a wide range of dermatological conditions.
View Article and Find Full Text PDFPreemptive Approach to Plerixafor Use Is Optimal in Patients With Relapsed/Refractory Germ Cell Tumors Undergoing Peripheral Blood Hematopoietic Stem Cell Collection: Effect on Collection Days, Yields, and Cost.
J Clin Apher
October 2024
Indiana University School of Medicine, Indianapolis, Indiana, USA.
Evidence describing the use of plerixafor in the off-label population of relapsed/refractory germ cell tumors (GCT) is limited. We aim to describe the effect of rescue versus preemptive plerixafor use on apheresis collection days, collection yields, and cost. We retrospectively collected data on 77 consecutive patients (at least 15 years of age) with GCT who underwent peripheral blood stem cell (PBSC) collection for autologous stem cell transplant between January 1, 2020 and May 1, 2022.
View Article and Find Full Text PDF